

**PE anti-human CD268 (BAFF-R)**

**Catalog # / Size:** 2184530 / 100 tests  
2184525 / 25 tests

**Clone:** 11C1

**Isotype:** Mouse IgG1, κ


**Immunogen:** BAFF-R-L1.2 transfectants

**Reactivity:** Human

**Preparation:** The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.

**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA).

**Concentration:** Lot-specific



Human peripheral blood lymphocytes stained with CD19 FITC and 11C1 PE

**Applications:**

**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. **Test size products are transitioning from 20 microL to 5 microL per test.** Please check your vial or your CoA to find the suggested use of this reagent per million cells in 100 microL staining volume or per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

**Application References:**

1. Ng LG, *et al.* 2004. *J. Immunol.* 173:807. (FC IHC)
2. Personal communication. (Block)

**Description:** B cell-activating factor receptor (BAFF-R) is a 19 kD type III membrane protein. It belongs to TNFR superfamily, also known as TNFRSF member 13C (TNFRSF13C), BAFF receptor 3 (BR3), or CD268. BAFF-R is expressed on mature B cells, B cell lymphoma, and T cell subset. BAFF-R is the major receptor for BAFF/BLys (or TALL-1, THANK) which binds to TACI and BCMA as well. The interaction of BAFF with BAFF-R promotes NF-κB activation and plays predominant roles in B-cell maturation and survival as well as costimulates T cell activation and proliferation. TRAF3 is a BAFF-R intracellularly associated protein, which negatively regulates BAFF-R-mediated NF-κB activation.

**Antigen References:**

1. Thompson JS, *et al.* 2001. *Science* 293:2108.
2. Ng LG, *et al.* 2004. *J. Immunol.* 173:807.
3. Rodig SJ, *et al.* 2005. *Human Pathol.* 36:1113.
4. Ye Q, *et al.* 2004. *Eur. J. I*